Which pharma issuers carry the most oncology biologic revenue at risk from the patent cliff, how imminent the biosimilar competition is, and whether the cliff is already in the price. Every figure is ticker-mapped and point-in-time, built from the FDA Purple Book, company filings and consensus. Direction is a headwind for originators (a tailwind for biosimilar developers). One screen, three lenses. Analysis, not a recommendation.
The interactive lenses above are the summary. The full PDF report has the exhaustive molecule-level cliff map, the two-wave timeline, market sizing and penetration curves, and the competitive biosimilar pipeline. Tell us where to send it and the download unlocks immediately.
Your download should begin automatically. If it doesn't, use the button below.
Download PDF again